Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
First patients enter pivotal phase II study of clofarabine
September 9th, 2004
Bioenvision, Ltd., (BIV) has announced that the first adult patients have been dosed on a pivotal European phase II study to evaluate its lead leukemia compound, clofarabine, in the treatment of adults with acute myeloid leukemia. The first patient, from Edinburgh, Scotland, will be joined by a further 64 patients from up to 11 other U.K. hospitals. Many patients with adult acute leukemia are elderly and very unwell as a result of their disease and may, therefore, be unable to tolerate intensive courses of chemotherapy. Such patients have very few treatment options that offer hope of a meaningful outcome, and they represent a real unmet clinical need. ...
Source: Blood Weekly (2004-09-09)
|
